In tablet manufacturing for bile acid replacement therapy, ox bile powder is processed as a high-dose active pharmaceutical ingredient in enteric-coated cores. The powder is pre-sieved through a 0.600 mm mesh, then blended with microcrystalline cellulose at 20–32% w/w, crospovidone at 2–4% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.5% w/w. Dry granulation on a roller compactor with a specific compaction force of 8–14 kN/cm and roll speed 5–12 rpm is preferred because wet granulation introduces water into the hygroscopic bile salt matrix and produces intragranular caking after storage at 40°C/75% RH. The granulate is compressed on an instrumented rotary tablet press at a precompression force of 2–4 kN, main compression force 8–15 kN, and turret speed 25–50 rpm to achieve tablet hardness 6–10 kp and friability ≤ 1.0% per USP <1216>. The tablets are coated with a methacrylic acid–ethyl acrylate copolymer dispersion, applied to 6–8% w/w weight gain in a perforated pan with inlet air at 35–45°C and product bed temperature 28–32°C. The finished enteric-coated tablet must retain at least 90% of the label claim after 2 h in 0.1 M HCl, then release ≥ 80% within 45 min in pH 6.8 phosphate buffer using USP <711> apparatus 2 at 75 rpm. Uniformity of dosage units is tested according to USP <905> with an acceptance value ≤ 15.0. The bovine-derived API must be accompanied by a Ph. Eur. 5.2.8 certificate of suitability stating the tissue source, rendering temperature, and country of origin, and microbial limits are set at total aerobic count ≤ 10³ CFU/g, total yeasts and moulds ≤ 10² CFU/g, and absence of Escherichia coli per USP <61> and <62>.

What Limits Capsule Fill Weight Variability in Ox Bile Powder–Pancreatin Blends?

Hard capsule manufacturing for digestive insufficiency regimens requires control of blend hygroscopicity because ox bile powder sorbs water rapidly at relative humidity above 40%, causing powder adhesion to dosator surfaces and fill weight drift. A low-shear tumble blender operating at 10–20 rpm for 15–20 min is used to combine ox bile powder at 35–50% w/w, pancreatin at 30–45% w/w, sodium bicarbonate at 10–15% w/w, microcrystalline cellulose at 10–20% w/w, and magnesium stearate at 0.5–1.0% w/w. The fill weight for a size 0 hard gelatin capsule is typically 250–350 mg, with a dosator pin height set to 2–5 mm and compression station adjusted to maintain powder plug density 0.55–0.70 g/cm³. Rooms are maintained at 20–25°C and 30–40% RH, and water activity of the blend should be below 0.4 to preserve enzyme activity. Capsule weight variation is measured by USP <905> with an acceptance value ≤ 15.0, and disintegration is performed in 0.1 M HCl at 37 ± 2°C with complete shell opening within 15 min per USP <701>. Because bile acids and pancreatin both influence the dissolution medium, the two-stage dissolution test uses 0.1 M HCl for 1 h, followed by pH 6.8 phosphate buffer, with sampling at 30 min and 60 min to quantify released bile acids by a validated HPLC method. Published data for this specific combination is limited; enzyme assay interference from bile salts must be evaluated before setting release limits. Microbial quality is controlled under USP <61> and <62> with the same limits applied to nonsterile oral products.

When patients cannot swallow intact tablets, ox bile powder is formulated as granules in unit-dose sachets for reconstitution into oral suspension. The top-spray fluid bed granulator is charged with ox bile powder at 45–60% w/w, mannitol at 25–40% w/w, and citric acid at 2–3% w/w. A binder solution of povidone K30 at 5% w/w in purified water is sprayed at 10–20 g/min with atomizing air pressure 1.0–1.5 bar, inlet air temperature 45–55°C, and product bed temperature 30–38°C, followed by drying to a final moisture content ≤ 2.0% w/w by Karl Fischer USP <921>. The dried granules are sieved through 0.800 mm and retained on 0.150 mm; the 0.150–0.800 mm fraction is filled into aluminum foil laminate sachets under room humidity ≤ 30% RH. The sachet material must have a water vapour transmission rate below 0.5 g/m²/day at 38°C/90% RH when tested by ASTM F1249. Published data for the specific moisture uptake threshold of ox bile powder granules is limited, but the hygroscopic bile salt fraction justifies a barrier overwrap and desiccant protection. For the finished granule, moisture content remains ≤ 2.5% w/w through the labelled shelf life, and dispersion in 10 mL of water occurs within 2 min. Dissolution in pH 6.8 phosphate buffer using USP <711> apparatus 2 at 50 rpm shows ≥ 80% released within 30 min. Uniformity of mass for single-dose sachets follows USP <905> with acceptance value ≤ 15.0, and microbial limits are those for nonsterile oral preparations per USP <61> and <62>.

Table 1 summarises representative quantitative boundaries across the solid oral dosage forms described above.

When Lyophilisation Replaces Terminal Sterilisation for Injectable Bile Acid Formulations

Injectable formulations of ox bile powder impose a different compliance burden because the nonsterile animal-derived API cannot be directly filled into parenteral containers. The solution is prepared in water for injection at 20–25°C with ox bile powder 50–150 mg per vial, mannitol 50–120 mg as cryoprotectant, disodium phosphate 10–20 mg as buffer, and sodium hydroxide q.s. to pH 8.0–8.5. The solution is prefiltered through a 0.45 μm polyvinylidene fluoride filter, then sterile-filtered through a 0.22 μm polyvinylidene fluoride filter at differential pressure ≤ 15 psi and filled into depyrogenated vials in an ISO 5 environment. A representative lyophilisation cycle is programmed with freezing at −40°C for 4 h, primary drying at shelf −10°C and chamber vacuum 50–150 μbar for 12–18 h, and secondary drying at +25°C for 6–8 h to a final moisture content ≤ 1.0% w/w. The finished lyophilizate is reconstituted in 10 mL of water for injection to a pH of 7.4–8.0 and osmolarity 280–320 mOsm/L. Particulate matter is tested by USP <788> with counts ≤ 6000 per container for particles ≥ 10 μm and ≤ 600 per container for particles ≥ 25 μm. Sterility is verified by USP <71> membrane filtration, and bacterial endotoxin is controlled under USP <85> at ≤ 0.5 EU/mL for a 10 mL injection. Pre-filtration bioburden must not exceed 10 CFU/100 mL under 21 CFR 211.113. Because unconjugated bile acid fractions have pKa values near 5.0–6.0, dilution with calcium-containing or low-pH infusions may cause precipitation; compatibility with normal saline is tested before clinical use, and calcium-free diluents are preferred. Published data for this specific injectable configuration is limited; viral safety follows ICH Q5A for bovine-derived materials and Ph. Eur. 5.2.8 documentation.

pH-Dependent Film Coating for Distal Ileum Bile Acid Release

Delayed-release tablet cores are granulated with an ethanolic povidone binder to limit water uptake before coating. The core formulation contains ox bile powder at 50–65% w/w, lactose monohydrate at 20–30% w/w, croscarmellose sodium at 2–4% w/w, povidone K30 at 3–5% w/w as binder, and magnesium stearate at 0.5–1.0% w/w. Granulation is performed in a high-shear mixer with impeller speed 150–250 rpm and chopper speed 1500–2500 rpm, using a 5% w/w povidone solution in anhydrous ethanol, followed by drying in a fluid bed at 40–45°C to final moisture ≤ 2.0% w/w. The cores are coated with a methacrylic acid–methyl methacrylate copolymer dispersion that dissolves above pH 7.0, applied to a weight gain of 8–10% w/w with triethyl citrate at 10–15% of polymer solids as plasticiser. Coating conditions are a spray rate of 5–10 g/min per kg of tablets, inlet air temperature 30–38°C, and bed temperature 23–27°C. The delayed-release tablet is tested by USP <711> two-stage dissolution: not more than 10% released in 0.1 M HCl after 2 h, followed by ≥ 70% released within 60 min in pH 7.4 phosphate buffer. Disintegration after the acid stage is confirmed in pH 7.4 buffer within 30 min per USP <701>. Hardness is maintained at 7–12 kp, and friability does not exceed 1.0% using USP <1216>. The terminal product is a non-sterile delayed-release tablet for oral administration, with the same TSE certification and microbial limits described for other nonsterile oral dosage forms.

Aqueous Suspension Compounding Requires Viscosity and Preservative Assessment Under USP <795>

In hospital compounding, ox bile powder is levigated with glycerin before incorporation into a suspending vehicle. A typical extemporaneous oral suspension contains ox bile powder at 100–250 mg/5 mL, carboxymethylcellulose sodium at 0.5–1.0% w/w as suspending agent, methylparaben at 0.1–0.2% w/w as preservative, and sodium citrate buffer to pH 7.0–7.5. Levigation with glycerin 1–2 mL is performed in a mortar, followed by geometric dilution and high-shear dispersion at 3000–5000 rpm for 5–10 min. The suspension is packaged in amber glass bottles and assigned a refrigerated beyond-use date of 14 days according to USP <795> unless stability data support a longer period. The final preparation is tested for appearance, pH 7.0–7.5, pourability, and dose uniformity after shaking; microbial challenge data for the preservative system are required if the beyond-use date exceeds 14 days. Bile acid hydrolysis in aqueous media can lower pH during storage, so a buffering capacity of at least 0.05 M is maintained. The compounded preparation is not intended for injection, and the label must state that the product is for oral use only and must be shaken before administration. Because the API is hygroscopic, the powder stock is stored in a desiccated container at 20–25°C and ≤ 40% RH before compounding.

Table 2 lists the principal compliance references applied across the dosage forms discussed.